Next Article in Journal
Have We Looked in the Wrong Direction for More Than 100 Years? Delayed Onset Muscle Soreness Is, in Fact, Neural Microdamage Rather Than Muscle Damage
Next Article in Special Issue
Carbosilane Dendrimers Loaded with siRNA Targeting Nrf2 as a Tool to Overcome Cisplatin Chemoresistance in Bladder Cancer Cells
Previous Article in Journal
Combining Medicinal Plant In Vitro Culture with Machine Learning Technologies for Maximizing the Production of Phenolic Compounds
Previous Article in Special Issue
Utilizing Iron for Targeted Lipid Peroxidation as Anticancer Option of Integrative Biomedicine: A Short Review of Nanosystems Containing Iron
 
 
Opinion
Peer-Review Record

Nanoparticles as Tools to Target Redox Homeostasis in Cancer Cells

Antioxidants 2020, 9(3), 211; https://doi.org/10.3390/antiox9030211
by Francesco Ciccarese 1, Vittoria Raimondi 1, Evgeniya Sharova 1, Micol Silic-Benussi 1 and Vincenzo Ciminale 1,2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Antioxidants 2020, 9(3), 211; https://doi.org/10.3390/antiox9030211
Submission received: 27 January 2020 / Revised: 20 February 2020 / Accepted: 29 February 2020 / Published: 4 March 2020

Round 1

Reviewer 1 Report

In this review, Ciminale et al. consider a variety of recent efforts to develop nanoparticle therapies that target tumor cells using ROS and redox approaches. The manuscript is appropriate in scope, clearly-written, and reasonably well-organized. Along with an introduction, sections are devoted to redox-modulating nanoparticles, nanoparticles used for photodynamic therapy, and nanoparticles that use redox phenomena for tumor targeting. The submission will be of interest to many in the field, but its utility would be significantly improved with some additions.

1) Including a figure demonstrating the “ROS rheostat’ concept and how it differs in tumor vs. normal cells would help the reader to understand the rationale for targeting the related pathways. 

2) A table should be included to help give context to the many nanoparticle systems described by the authors. Within each category (ROS modulators, PDT mediators, and redox-targeted systems), providing information such as nanoparticle composition, carrier system (if applicable), putative mechanism of action, model used for validation (cells or animal model, tumor type), and the relevant references would allow the reader to efficiently compare the types of carriers being reviewed.

Minor point (line 60): The size range for nanoparticles is typically 1-1000 nanometers. Many nanoparticle systems, especially polymer and lipid-based examples, are larger than 100 nm.

Author Response

Please see the attachment. 

Author Response File: Author Response.pdf

Reviewer 2 Report

In this review the authors report recent anticancer therapies based on nanoparticles. The focus is mainly based on the ability of NP to burst the redox state of cancer cells and their use for site-specific drug delivery.

The review is well conceived and clear, however, I suggest to insert some schemes regarding the results depicted in the paragraphs 2 and 4 for a quick highlight of the presented results.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

I appreciate the authors' efforts to improve the manuscript. It is suitable to be published in its current form.

Back to TopTop